Oncology

Experts say a cancer care revolution is here. Here’s a closer look at some advancements in cancer treatments to watch.

Key takeaways for healthcare executives from Bruno Medeiros, MD, associate professor of medicine (hematology) at the Stanford University Medical Center and director of Cancer Center Infusion Area Treatment Services at Stanford Cancer Center.

Acute myeloid leukemia experts share promising new developments on the oncology horizon.

Physicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.

There are several possible reasons that breastfeeding may influence breast cancer risk, according to the American Institute of Cancer Research. Find out what they are.

New research shows that these certain patients with breast cancer can benefit from genetic testing for all breast cancer genes.

The medication’s ability to reduce inflammation sited as one possible explanation.

Study highlights the need for services and research for this understudied population.

Study shows Clovis Oncology’s rucaparib shows clinically meaningful impact in delaying disease recurrence in ovarian cancer.

Understanding genetic variations and tumor differences in black women with breast cancer could lead to personalized diagnosis and treatment.

New research shows hypertension, diabetes influence survival of ovarian cancer patients in different ways.

Alcohol consumption is known to be a risk factor for breast cancer based on studies predominantly done in white women. Now, a University of North Carolina Lineberger Comprehensive Cancer Center study has found the same risk exists for black women.

A new study provides new insights into the epidemiology of breast cancer among the most prominent Asian-American ethnic groups in California.

New findings reveal this genetic test to assess breast cancer risk could be more effective than others.

Oncology is a complex and rapidly-evolving management challenge for payers.

Biomarker testing for harmful genetic mutations provides the opportunity to identify at-risk individuals who might benefit from risk modification strategies and/or enhanced disease screening.

Inherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.

Investigational gene therapies might reduce the suffering and death caused by this genetic disease.

As development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care-and discussing how to efficiently share the massive amounts of genomic data that will result.

There now exist numerous treatment options for multiple myeloma but how best to sequence them is still under study

In this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.

An ASH presenter describes how better health IT and better institutional practices are necessary to leverage EHRs for quality of care.

Novel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.

Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.

This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.